PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

February 29, 2004

Conditions
Critically IllDeep Venous Thrombosis
Interventions
DRUG

Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)

Trial Locations (16)

2065

Royal North Shore Hospital of Sydney, Sydney

3181

Royal Alfred Hospital, Melbourne

B3H 3A7

Queen Elizabeth II Health Science Centre, Halifax

L8N 3Z5

Hamilton Health Science Centre - Hamilton General Hospital, Hamilton

Hamilton Health Science Centre - McMaster University, Hamilton

L8N 4A6

Hamilton Health Science Centre - Henderson Hospital, Hamilton

St. Joseph's Hospital, Hamilton

K1H 8L6

Ottawa General Hosptial, Ottawa

K1Y 4E9

Ottawa Civic Hospital, Ottawa

M4N 3M5

Sunnybrook & Women's College Health Science Centre, Toronto

M5G 1X5

Mount Sinai Hospital, Toronto

M5G 2C4

University Health Network - Toronto General Hospital, Toronto

J4V 2H1

Hopital Charles LeMoyne, Greenfield Park

H1T 2M4

Hopital Maisonneuve Rosemont, Montreal

H4J 2C5

Hopital Sacre Couer, Montreal

G1J 1Z4

Centre Hospitalier Affilie- Enfant Jesus, Québec

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Canadian Critical Care Trials Group

OTHER

lead

Hamilton Health Sciences Corporation

OTHER

NCT00182364 - PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot) | Biotech Hunter | Biotech Hunter